Design, synthesis and biological activity of 3-pyrazine-2-yl-oxazolidin-2-ones as novel, potent and selective inhibitors of mutant isocitrate dehydrogenase 1
Tianfang Ma(China Pharmaceutical University), Xiaoming Zha(China Pharmaceutical University), Andreas von Deimling(Heidelberg University), Qihua Zhu(China Pharmaceutical University), Yueqing Gu(China Pharmaceutical University), Stefan Pusch(German Cancer Research Center), Yungen Xu(China Pharmaceutical University), Lijun Yang(Chinese Academy of Medical Sciences & Peking Union Medical College), Fangxia Zou(China Pharmaceutical University)
Cited by 14
Related Papers
EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood
|Nature Reviews Clinical Oncology|2020|1.9k
Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions
|Neuro-Oncology|2020|1.1k
K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas
|Acta Neuropathologica|2012|1k
Practical implementation of DNA methylation and copy-number-based CNS tumor diagnostics: the Heidelberg experience
|Acta Neuropathologica|2018|584
Characterization of R132H Mutation‐specific IDH1 Antibody Binding in Brain Tumors
|Brain Pathology|2009|523